The Organization file
Novo Nordisk 20 stories · 5 sources · updated every week
Novo Nordisk's stock tumbled on September 21-22 as investors questioned its post-2023 growth strategy beyond Wegovy, which loses exclusivity in the early 2030s. CEO Lars Fruergaard Jørgensen defends diversification and M&A, while the company rebrands Wegovy for "customers" to expand its GLP-1 market. Watch for Novo's Q4 earnings to see how its 61% U.S. GLP-1 share and 80%+ new oral prescription share translate into sustained growth.
☆ Watch this file Timeline Oct 28 Lilly's retatrutide beats Ozempic on sugar and weight STAT News
Oct 21 OpenAI buys Orchestra Bio to boost Rosalind AI TechCrunch
Oct 19 Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly CNBC
Oct 05 STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more STAT News
Sep 28 Novo Nordisk Rebrands Wegovy as Lifestyle Drug STAT News
Sep 25 STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more STAT News
Sep 25 Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s CNBC
Sep 24 Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution STAT News
Sep 22 Novo Nordisk Stock Tumbles as CEO Defends Diversification Google News Business
Sep 22 Novo CEO sees weight-loss pills catching up to injectables by 2030 Globe and Mail Business
Sep 22 STAT+: Did the Trump administration just cut Novo a huge financial win? STAT News
Sep 22 Viking's VK2735 Obesity Data Spurs Stock Surge, Lilly and Novo Fall Google News Business
Sep 22 Novo CEO defends diversification, eyes M&A beyond obesity CNBC
Sep 22 Should we use GLP-1 drugs to treat obesity in children? New Scientist
Sep 21 Novo Nordisk Shares Slump on Pipeline, Pricing Grilling Google News Business
Sep 21 Novo Stock Tumbles on Post-Wegovy Growth Plan Google News Business
Sep 21 Novo Nordisk Stock Tumbles on Post-Wegovy Plan Google News Business
Sep 21 STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work STAT News
Sep 21 Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs CNBC
Sep 18 Anthropic Confirms Bay Area Wet Biology Lab TechCrunch
Shows up with